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Angiogenesis is controlled by physical interactions between cells and extracellular matrix as well as soluble angiogenic factors, such as VEGF. However, the mechanism by which mechanical signals integrate with other microenvironmental cues to regulate neovascularization remains unknown. Here we show that the Rho inhibitor, p190RhoGAP (also known as GRLF1), controls capillary network formation in vitro in human microvascular endothelial cells and retinal angiogenesis in vivo by modulating the balance of activities between two antagonistic transcription factors, TFII-I (also known as GTF2I) and GATA2, that govern gene expression of the VEGF receptor VEGFR2 (also known as KDR). Moreover, this new angiogenesis signalling pathway is sensitive to extracellular matrix elasticity as well as soluble VEGF. This is, to our knowledge, the first known functional cross-antagonism between transcription factors that controls tissue morphogenesis, and that responds to both mechanical and chemical cues.
Deregulation of angiogenesis-the growth of blood capillariescontributes to the development of many diseases, including cancer, arthritis and blindness 1, 2 . Most US Food and Drug Administration (FDA)-approved angiogenesis inhibitors target the oxygen-sensitive vascular endothelial growth factor, VEGF; however, neovascularization is also controlled by other microenvironmental signals, including mechanical forces conveyed by extracellular matrix (ECM). For example, although capillary development is driven by angiogenic mitogens, cell sensitivity to these soluble cues can be modulated by physical interactions between cells and ECM that alter cell shape and cytoskeletal structure [3] [4] [5] [6] [7] [8] . Similar changes in capillary cell shape and function can be produced by changing ECM elasticity, adhesivity or topography, applying mechanical stresses, or altering cell-generated traction forces [3] [4] [5] [6] [7] [8] . Mechanical tension also stimulates capillary growth and vascular remodelling in vivo 9 , and regional variations of ECM mechanics and cell shape seem to mediate how neighbouring cells undergo localized differentials of growth and differentiation that drive three-dimensional tissue pattern formation 10, 11 . However, the mechanism by which mechanical signals conveyed by ECM converge with those elicited by growth factors to control gene transcription required for angiogenic control remains unknown.
VEGF and its receptor VEGFR2 are of particular importance in angiogenesis because they are essential for normal blood vessel development 12, 13 , and deregulation of these factors leads to various pathological conditions 1, 2, 14 . We therefore investigated the role of VEGF and VEGFR2 in the mechanism by which these mechanical forces regulate capillary development. Analysis of cellular mechanotransduction during angiogenesis has shown that the small GTPase Rho mediates growth control in vitro 10, 15 , as well as blood vessel development in vivo 9 , by modulating the mechanical force balance that governs cell shape. Stress-induced distortion of the capillary cell cytoskeleton regulates Rho activity by controlling its upstream inhibitor, p190RhoGAP 16 . p190RhoGAP was shown to bind to the transcription factor TFII-I and sequester it in the cytoplasm of fibroblasts 17 , and TFII-I is a multifunctional transcription factor that regulates VEGFR2 expression in large vessel endothelial cells 18, 19 . Although it remains unknown whether it has a role in angiogenesis, TFII-I deletions are associated with cardiovascular defects 20 . These findings raise the possibility that TFII-I might also contribute to intracellular signalling mechanisms triggered by mechanical forces during vascular network formation.
p190RhoGAP and TFII-I regulate VEGFR2
To explore whether p190RhoGAP modulates vascular development by altering gene transcription, we knocked down p190RhoGAP in human microvascular endothelial (HMVE) cells using short-interfering RNA (siRNA). TFII-I protein levels were approximately 1.5 times higher in the nuclear fraction of knockdown cells ( Supplementary Fig. 2a ), and this was confirmed by fluorescence microscopy ( Supplementary Fig.  2b ). As first shown in fibroblasts 17 , we found that p190RhoGAP coprecipitates with TFII-I (and vice versa) ( Supplementary Fig. 2c ), suggesting that p190RhoGAP may also bind TFII-I and sequester it in the cytoplasm of human capillary cells.
TFII-I upregulates VEGFR2 protein expression in human aortic endothelial cells by binding to the VEGFR2 promoter 18 . However, TFII-I knockdown in our HMVE cells increased (rather than decreased) VEGFR2 messenger RNA and protein levels by two-to threefold relative to control cells, and overexpressing TFII-I (delta isoform 21 ) using lentiviral transduction produced the opposite effect ( Fig. 1a and Supplementary Fig. 3a ). This may be due to the fact that macrovascular and microvascular endothelial cells undergo distinct morphogenetic programs (produce large tubes versus branching capillaries).
TFII-I binds to the initiator (Inr) region of the VEGFR2 gene promoter, and smaller portions of this promoter (human VEGFR2: 2225 to 1268, 2570 to 1268, and 2780 to 1268) have similar or greater activity compared to the full-length promoter (4 kilobases (kb) long) using a luciferase assay in human umbilical vein endothelial (HUVE) cells, TFII-I knockdown increased, and overexpression of TFII-I using DNA transfection decreased, VEGFR2 promoter activity by 1.5 to twofold and one-fifth normal levels, respectively ( Supplementary  Fig. 3b ). The promoter-less pGL3 basic reporter showed no promoter activity (data not shown). Moreover, mutagenesis of the VEGFR2 Inr (2780 to 1268; 780MUT) decreased promoter activity in both control and TFII-I knockdown cells ( Supplementary Fig. 3b ), confirming that TFII-I decreases VEGFR2 promoter activity through the Inr region. Importantly, the specificity of these effects of TFII-I knockdown was confirmed by demonstrating that reconstitution of mouse TfII-I can reverse these effects ( Supplementary Fig. 3c ).
We next addressed whether p190RhoGAP stimulates VEGFR2 expression by restricting the nuclear translocation of TFII-I ( Supplementary Fig. 2a, b) . TFII-I knockdown increased, and p190RhoGAP knockdown decreased, VEGFR2 promoter activity (2780 to 1268) relative to control cells (Supplementary Fig. 3d ).
The double knockdown of p190RhoGAP and TFII-I exhibited the same stimulation as observed in the TFII-I knockdown cells ( Supplementary Fig. 3d ). However, p190RhoGAP knockdown did not decrease VEGFR2 mRNA and protein levels; in fact, it increased VEGFR2 protein levels ( Fig. 1b and Supplementary Fig. 3d ). Moreover, p190RhoGAP and TFII-I double knockdown produced similar or slightly higher levels of VEGFR2 mRNA and protein expression ( Fig. 1b and Supplementary Fig. 3d ) compared to either p190RhoGAP or TFII-I knockdown alone. These results raised the intriguing possibility that an antagonist of TFII-I activity might exist that also contributes to p190RhoGAP-dependent control of VEGFR2 expression.
GATA2 upregulates VEGFR2
GATA2 is another transcription factor that binds to the VEGFR2 promoter and regulates its activity 23, 24 . Because many GATA family members antagonize the effects of other transcription factors at promoter sites [25] [26] [27] [28] , we explored whether GATA2 mediates p190RhoGAP-dependent control of VEGFR2 expression by opposing TFII-I activity. When p190RhoGAP was knocked down, GATA2 levels in the nucleus increased markedly (.10-fold) relative to control cells even though total GATA2 levels remained the same, as shown by immunoblotting ( Supplementary Fig. 3e ) and fluorescence microscopy ( Fig. 1c) . p190RhoGAP also co-immunoprecipitated with GATA2 and vice versa ( Supplementary Fig. 3f ). Notably, this increase in nuclear GATA2 was significantly higher than the 1.5-fold increase in nuclear TFII-I produced using p190RhoGAP siRNA ( Supplementary Fig. 2a , b), suggesting that p190RhoGAP binds and sequesters GATA2 in the cytoplasm more efficiently than TFII-I in capillary cells. GATA2 knockdown using siRNA decreased VEGFR2 promoter activity, as well mRNA and protein levels ( Supplementary Fig. 4a, b) as previously observed 23 , whereas GATA2 overexpression produced the opposite effect. These effects of GATA2 siRNA on VEGFR2 promoter activity and protein expression were specific as they were reversed by reconstitution of the mouse Gata2 gene (Supplementary Fig. 3c ). p190RhoGAP knockdown increased the expression of VEGFR2 mRNA and protein, and double knockdown with GATA2 inhibited these effects ( Fig. 1d and Supplementary Fig. 4c ). Thus, GATA2 seems to upregulate VEGFR2 promoter activity and mediate the effects of p190RhoGAP on VEGFR2 gene expression in capillary cells. However, knockdown of p190RhoGAP, which releases more GATA2 than TFII-I and increases VEGFR2 expression, did not increase VEGFR2 promoter activity ( Supplementary Fig. 3d ). This may be because cellular TFII-I levels are five times higher than GATA2 levels (data not shown). We also measured VEGFR2 promoter activity using only a portion of its promoter, and hence, TFII-I and GATA2 may also exert regulatory activities at other promoter sites; alternatively, p190RhoGAP might elicit signals that influence mRNA stability.
We next determined whether GATA2 and TFII-I directly antagonize each other. Simultaneous knockdown of TFII-I and GATA2 abrogated each other's effects on VEGFR2 promoter activity (Fig. 1e ), mRNA production ( Fig. 1f ) and protein expression levels ( Supplementary  Fig. 4e ), and simultaneous overexpression of TFII-I and GATA2 produced similar effects ( Supplementary Fig. 4d , e). These effects were specific for VEGFR2 as the knockdown of TFII-I or GATA2 did not alter the expression of VEGFR1 (also known as FLT1) or VEGFR3 (FLT4) in HMVE cells ( Supplementary Fig. 5a ). Notably, although p190RhoGAP is a Rho inhibitor, altering Rho activity with constitutively active RHOA, membrane-permeable C3 exoenzyme or siRNA directed to another Rho-inhibiting RhoGAP (p73RhoGAP, also known as ARHGAP24) 29 did not change VEGFR2 mRNA or protein levels ( Supplementary Fig. 5b, c) . Thus, p190RhoGAP seems to control VEGFR2 expression solely by its ability to sequester these transcription factors.
Analysis of this mechanism of functional cross-antagonism demonstrated that GATA2 and TFII-I associate with each other, as GATA2 co-immunoprecipitated with TFII-I, and vice versa (Supplementary a, VEGFR2 and TFII-I mRNA levels in cells treated with TFII-I siRNA or lentiviral vectors (virus) relative to control cells (*P , 0.05; unpaired Student's t-test is used throughout). b, Immunoblots showing VEGFR2, TFII-I, p190RhoGAP (p190) and GAPDH protein levels in cells treated with TFII-I or p190RhoGAP siRNAs, or both. c, Immunofluorescence micrographs showing GATA2 distribution and nuclear 4,6-diamidino-2-phenylindole (DAPI) staining in control and p190RhoGAP knockdown cells cultured with 0.3% serum (scale bar, 5 mm). d, VEGFR2 mRNA levels in cells transfected with p190RhoGAP siRNA alone or with GATA2 siRNA (*P , 0.01). e, f, VEGFR2 promoter activities (e) and mRNA levels (f) in cells transfected with GATA2 or TFII-I siRNA alone or in combination (*P , 0.01, **P , 0.05). g, ChIP analysis showing VEGFR2 promoter coimmunoprecipitating (IP) with GATA2 or TFII-I antibodies in cells transfected with TFII-I or GATA2 siRNA (n 5 3). Ct, control. All error bars are s.e.m. Fig. 6a ). Furthermore, GATA2 even binds to TFII-I in p190RhoGAP knockdown cells and to p190RhoGAP in TFII-I knockdown cells ( Supplementary Fig. 6b ). These results indicate that the various heterodimeric combinations of TFII-I, GATA2 and p190RhoGAP exist in separate pools, and that these heterodimers then associate to form a larger ternary complex ( Supplementary Fig. 1 ). Chromatin immunoprecipitation (ChIP) analysis showed that TFII-I knockdown cells exhibited increased recruitment of GATA2 to the GATA binding site (2150 to 1150) compared to control cells and vice versa (Fig. 1g) , whereas control IgG did not immunoprecipitate these DNAs (Fig. 1g) . p190RhoGAP knockdown decreased the recruitment of TFII-I, but not GATA2, to this promoter site, which resulted in a relative net increase in GATA2 recruitment to this site ( Supplementary Fig. 6c ). TFII-I and GATA2 therefore compete with each other for occupancy of a common region of the VEGFR2 promoter, which is controlled by p190RhoGAP.
Mechanical control of VEGFR2 Soluble growth factors, integrin binding to ECM, and mechanical distortion of the cytoskeleton all regulate p190RhoGAP activity in cells 30 . Cell binding to growth factors and adhesive contact formation with ECM also control VEGFR2 expression 31, 32 , and soluble mitogens (5% serum plus VEGF, bFGF and PDGF) increase nuclear translocation of TFII-I and GATA2 in HMVE cells ( Supplementary Fig. 7a ). We therefore next explored whether changes in mechanical interactions between cells and ECM regulate this pathway as well. When HMVE cells were cultured in the absence of mitogens on fibronectincoated polyacrylamide gels with different elasticity (Young's moduli (stiffness) of 150 to 4,000 Pa), they appeared round on the soft gels, whereas they flattened on the stiffer gels, as previously observed 33, 34 , which is based on differences in their ability to physically resist cell traction forces 8, 33, 34 . Nuclear GATA2 levels were significantly higher in cells on the stiffer gels, whereas nuclei exhibit similar high levels of TFII-I regardless of ECM stiffness (Fig. 2a) , and similar results were obtained in the presence of several soluble factors or VEGF alone (Supplementary Fig. 7b ). Moreover, VEGFR2 mRNA and protein levels were higher in cells on the stiffer (4,000 Pa) gels ( Fig. 2b and Supplementary Fig. 7c ). Interestingly, this relatively stiff, but still compliant, ECM gel seemed to support optimal responsiveness of this signalling pathway because VEGFR2 mRNA and protein levels were significantly lower in cells cultured on rigid glass ECM substrates (Fig. 2b, and Supplementary Fig. 7c ). ECM elasticity may therefore regulate VEGFR2 expression preferentially via GATA2, particularly over the stiffness range analysed in this study.
Further analysis showed that TFII-I knockdown restored VEGFR2 expression in cells on soft gels to levels similar to those in cells on stiff gels, and double knockdown with GATA2 (which decreases VEGFR2 expression) abrogated the effects of TFII-I (Fig. 2c and Supplementary  Fig. 7d ). p190RhoGAP knockdown also increased the expression of VEGFR2 mRNA and protein, and double knockdown with GATA2 inhibited these effects on soft gels (Fig. 2d and Supplementary Fig. 7d ). These data indicate that p190RhoGAP and the mutually antagonistic TFII-I and GATA2 transcription factors mediate the effects of ECM elasticity on VEGFR2 expression in these cells, which is preferentially shifted to GATA2 on stiffer gels.
Transcriptional control of angiogenesis
We next explored the functional relevance of this antagonism between GATA2 and TFII-I by analysing capillary cell migration and differentiation (tube formation) in vitro. When HMVE cells were transfected with TFII-I siRNA and analysed using the transwell migration assay, VEGF-stimulated cell motility increased by twofold, whereas this induction was prevented by knocking down GATA2 simultaneously with TFII-I (Fig. 3a) . The VEGFR2 kinase inhibitor SU5416 totally inhibited the migration of these cells (Fig. 3a) , confirming that these effects are mediated by VEGFR2 signalling. Moreover, GATA2 overexpression increased VEGF-induced cell migration by threefold, and the simultaneous overexpression of GATA2 and TFII-I abolished these effects (Fig. 3a) . These effects were specific in that reconstitution of TfII-I or Gata2 reversed the effects of knocking down TFII-I or GATA2, respectively ( Supplementary Fig. 8a ).
We then studied capillary tube formation by HMVE cells cultured within the ECM gel Matrigel, which supports angiogenesis in part because of its flexibility. Tube formation was stimulated by VEGF in a dose-dependent manner, whereas bFGF (also known as FGF2) and PDGFB were ineffective, and the effects of VEGF were inhibited by SU5416 (Supplementary Fig. 8b ). GATA2 knockdown and TFII-I overexpression suppressed VEGF-stimulated capillary development, and once again either knocking down or overexpressing both transcription factors simultaneously negated these effects ( Fig. 3b and Supplementary Fig. 8c ). TFII-I knockdown or GATA2 overexpression alone did not produce significant effects on tube formation, apparently because it was already optimally stimulated under these conditions (Fig. 3b) ; knockdown or overexpression of p190RhoGAP also did not alter tube formation (Supplementary Fig. 8d ). Thus, functional antagonism between GATA2 and TFII-I at the level of VEGFR2 transcription translates into biologically relevant changes in capillary cell behaviour that are required for formation of threedimensional capillary networks.
Control of angiogenesis in vivo
We next examined whether ECM mechanics govern vessel formation in vivo using a modified Matrigel implant assay. Maximal levels of cell infiltration, capillary blood vessel formation, and VEGFR2 expression were observed in Matrigel with intermediate stiffness (800 Pa) compared to cells in more or less rigid gels (900 or 700 Pa, respectively) (Fig. 4a, c and Supplementary Fig. 9a, b) . VEGFR2, GATA2 and TFII-I all localized within cells lining CD31-positive staining microvessels ( Supplementary Fig. 9c ). The finding that the optimal ECM stiffness required for angiogenesis in vivo (800 Pa) was different from that observed in vitro (4,000 Pa) is probably due to different requirements by cells when cultured on two-dimensional ECM versus a three-dimensional ECM gel; it may also relate to how the Matrigel is remodelled over time in vivo.
We next performed siRNA-mediated gene knockdown in the in vivo Matrigel assay. Notably, TfII-I knockdown increased cell infiltration, capillary vessel formation and VEGFR2 expression by cells in the soft gels so that it mimicked the behaviour of cells on the intermediate stiffness gel, whereas Gata2 knockdown produced the opposite effects (Fig. 4b, d and Supplementary Fig. 10a ), and p190RhoGAP knockdown also increased the level of vessel formation in the soft gels ( Supplementary Fig. 10b ). These results indicate that TFII-I, GATA2 and p190RhoGAP mediate the signalling effects of ECM mechanics on vessel formation in vivo.
To unequivocally confirm the functional and clinical relevance of the regulatory interactions between TFII-I, GATA2 and p190RhoGAP, we modulated their expression in the neonatal mouse retina because angiogenesis in this growing organ is tightly regulated by VEGF and its receptors 14, 35, 36 . TFII-I, GATA2 and VEGFR2 localized to the three layers of the retina where blood vessels are located in postnatal day (P)15 mice ( Supplementary Fig. 11a, b) . Consistent with in vitro data, knocking down TfII-I using intravitreal injection of siRNA to P14 mice resulted in increased Vegfr2 expression and the appearance of highly tortuous dilated vessels and a significant increase in vascular density in the retina, whereas Gata2 knockdown suppressed Vegfr2 expression, disrupted capillary network formation and decreased vascular density ( Fig. 5a and Supplementary Fig. 12a, b) . Knockdown of p190RhoGAP also increased Vegfr2 expression and vessel density, but it resulted in a slightly different capillary growth pattern, perhaps in part because of its known effects on vascular permeability 37 ( Fig. 5a and Supplementary  Fig. 12a, b) . Similar effects were observed in earlier (P5) retina that contain rapidly growing microvessels (Supplementary Fig. 13 ). Furthermore, overexpression of human TFII-I and GATA2 produced opposite effects on vascular density in P14 retina, and simultaneous overexpression of both factors abolished these effects, confirming our in vitro findings (Fig. 5b and Supplementary Fig. 12c ). Knockdown of p190RhoGAP or TfII-I did not significantly change Vegf expression levels in the retina, whereas Gata2 knockdown increased (rather than decreased) its expression (Supplementary Fig. 12d ). The decrease of Vegfr2 expression seems to be sufficient to abrogate this Vegf response in Gata2 knockdown retina, and thereby inhibit angiogenesis. Hence, p190RhoGAP controls Vegfr2 expression and vascular development by modulating the balance between TFII-I and GATA2 activities such that TFII-I activity dominates (and Vegfr2 expression is suppressed) in the retina.
Discussion
Transcription factors change their activities in a spatio-temporal manner during development, and thereby specify cell fate 38, 39 . Here we show that p190RhoGAP, which has been shown to be regulated by growth factors, ECM binding and cytoskeletal distortion, also controls VEGFR2 expression, as well as angiogenesis in vitro and in vivo, by altering the balance between two mutually antagonistic transcription factors: TFII-I and GATA2 ( Supplementary  Fig. 1) . Moreover, we demonstrate that p190RhoGAP and this downstream transcriptional control mechanism are regulated by mechanical signals conveyed by variations in ECM elasticity. This mechanism is analogous to other developmental mechanisms used by haematopoietic cells and mammary epithelium 28, [38] [39] [40] ; however, this is, to our knowledge, the first demonstration that transcriptional cross-antagonism can govern histodifferentiation and tissue morphogenesis, and be sensitive to mechanical as well as chemical cues.
Our data suggest that an appropriate level of ECM stiffness may be required for optimal VEGFR2 expression and vascular development in vitro and in vivo. In fact, the fates of different cell types are exquisitely sensitive to distinct ECM elasticity values that often match those exhibited by their host tissues 41 . Abrupt local changes in ECM mechanics also accompany the switch between active growth and quiescent differentiation of functional capillary networks in living tissues 42 . Cell rounding suppressed p190RhoGAP activity within 1 to 2 h by altering its binding to the cytoskeletal protein filamin 16 . A similar cytoskeleton-based effect could mediate the effect of ECM elasticity on p190RhoGAP activity at later times, and thereby control the TFII-I:GATA2 balance and VEGFR2 transcription. Because VEGFR2 is expressed in neurons as well as in endothelial cells in the retina, some of the effects of gene knockdown we observed may not be specific to capillary cells. However, even these alterations might be relevant for control of vascular development because neuron-vessel interactions are indispensable for normal microvasculature function and patterning 43 . These data demonstrate a previously unknown mechanosensitive signalling pathway that controls VEGFR2 promoter activity and expression, and which represents a point of convergence for all three classes of microenvironmental signals that regulate capillary morphogenesis. Development of specific modifiers of this pathway could therefore lead to new therapeutic approaches for various angiogenesis-dependent diseases, including proliferative retinopathy, arthritis and cancer, in the future.
METHODS SUMMARY
Expression of TFII-I, GATA2 and VEGFR2 were evaluated by quantitative PCR with reverse transcription (qRT-PCR) and immunoblotting. A luciferase reporter assay was used to measure VEGFR2 promoter activity. To test the effects of TFII-I and GATA2 on VEGFR2 expression and angiogenesis in vitro, siRNAmediated knockdown or lentiviral transduction was performed in HMVE cells. In vitro analysis of angiogenesis was carried out using transwell migration and Matrigel tube formation assays, and similar results were obtained using both native and growth factor-reduced forms of Matrigel. A subcutaneous Matrigel angiogenesis assay was used to analyse the effects of ECM mechanics on capillary formation in vivo. Retinal vessel formation was also studied in newborn C57BL/6 mice, and gene expression was manipulated in whole living retina by intravitreal injection of siRNA or DNA into the eye at P5 or P14.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
METHODS
Materials. Anti-GATA2 polyclonal antibody was from Abcam, anti-HA monoclonal antibody was from Covance, monoclonal antibodies against TFII-I, p190RhoGAP, PECAM (CD31) and paxillin were from Transduction laboratory, anti-GAPDH antibody was from Chemicon, anti-lamin monoclonal antibody was from Upstate, anti-VEGFR2 antibody was from Cell Signaling, and antiMyc antibody was from Santa Cruz. Protein G-sepharose was from AmershamPharmacia and SU5416 was from Calbiochem. VEGF-A was from NIH; bFGF and PDGF were from Roche and Biovision, respectively. Cell permeable Rho inhibitor (C3 exoenzyme) was from Cytoskeleton. HMVE and HUVE cells (Cambrex) were cultured in EBM2 medium containing 5% FBS and growth factors (VEGF, bFGF and PDGF) for all experiments 16 except the nuclear translocation assays in which we used EBM2 with 0.3% serum. Cells were plated on plastic dishes for molecular biochemical assays, and on fibronectin-coated glass coverslips for cell staining, except for experiments using flexible substrates. Plasmid construction and gene knockdown. pGL3-VEGFR2-225 (2225 to 1268), 2570 (2570 to 1268), 2780 (2780 to 1268) were constructed using RT-PCR with genomic DNA from HUVE cells, and subcloned into pGL3 vector (Promega) at the SacI/XhoI sites. For pGL3-VEGFR2-780Inr-MUT, the Inr (CACT to GTGC) was point mutated using the QuickChange mutagenesis kit (Stratagene). For lentivirus construction, human Myc-TFII-I (delta isoform), HA-GATA2 and HA-p190RhoGAP were constructed by PCR using template plasmids from Open Biosystems and H. Sabe (Osaka Bioscience Institute). For retrovirus construction, mouse Myc-TfII-I (gamma isoform) and HA-Gata2 were constructed using template plasmids from Open Biosystems and T. Nakano (Osaka University), respectively. To generate the delta isoform of mouse TFII-I, 256-274 and 294-314 amino acids were deleted from the gamma isoform. Construction of constitutively active RhoA and the generation of viral vectors were previously described 37 . For gene knockdown, siRNA transfection was performed as described 16 . siRNA sequences are shown in Supplementary  Table 1 . Biochemical methods. For luciferase reporter assays, HUVE cells were transfected using Superfect (QIAGEN) and assayed using Dual-Luciferase reporter assay kit (Promega). Luciferase activity was measured in duplicate using a luminometer (TD20/20, Turner Designs). Cytoplasmic and nuclear cell extracts were prepared with a Nuclear Extraction Kit (Chemicon). Molecular biological methods. Quantitative RT-PCR was performed with the Quantitect SYBR Green RT-PCR kit (QIAGEN) using ABI7300 real-time PCR system (Applied Biosystems); b2 microglobulin or cyclophilin controlled for complementary DNA content. The primers used are shown in Supplementary  Table 2 . For ChIP assay, DNA from HMVE cells transfected with control or TFII-I siRNA was immunoprecipitated with the GATA2 antibody or control immunoglobulin (Jackson Immuno Research), or vice versa, according to the manufacturer instructions (Active Motif). The GATA2-and TFII-I-binding region was amplified using primers, 59-GTAAATGGGCTTGGGGAGCTG-39 and 59-GGCG-GCTGCAGGGGCGTCT-39. Cell analysis methods. Flexible polyacrylamide gel culture substrates were prepared as described 34, 44 and coated with fibronectin (1 mg cm
22
). Substrate flexibility was controlled by varying the acrylamide (2-4%) and the bis-acrylamide (0.1-0.5%) concentration; the Young's modulus (stiffness) was determined as described 45 . HMVE cells were cultured for 6 h on the gels and immunostaining was performed and analysed using confocal Leica SP2 microscope 15 . For cell migration assay, transwell membranes (Coster) were coated with 0.5% gelatin, and cells were seeded (10 5 cells per 100 ml) with 0.3% FBS in EBM2. Cells were stained with Giemsa solution 16 h later, and counted in ten random fields (3400). For the in vitro angiogenesis assay, HMVE cells (10 4 cells per 150 ml of EBM-2) were plated on Matrigel (BD Biosciences), and incubated for 12-16 h in the presence of VEGF (10 ng ml 21 ); tube formation was assessed in ten random fields (34) . In vivo Matrigel implantation assay. All animal studies were reviewed and approved by the Animal Care and Use Committee of Children's Hospital Boston. Matrigel plugs with different elasticity were cast in 4 3 4 mm (internal diameter 3 height) polydimethylsiloxane moulds and incubated at 37 uC overnight before implanting them subcutaneously on the backs of C57BL/6 mice. The stiffness of the Matrigel was modulated over a narrow range (that is, without making it rigid) by altering ECM protein cross-linking using a microbial transglutaminase (2.5-20 U g
21
; Ajinomoto) 46 . The storage modulus (G') of the gels was measured with an AR-G2 rheometer (TA Instruments) using a standard 20-mm aluminium parallel plate (1 Hz, 1% strain, 37 uC). The Young's modulus for an equivalent polyacrylamide gel was calculated by E 5 2G'(1 1 n) using an average Poisson's ratio (n) of 0.5. After 7 days, the polydimethylsiloxane moulds containing the gel plugs were collected, fixed and cryosectioned. H&E staining and immunostaining were performed as described 15, 47 . Stacks of optical sections (20-mm thick) were compiled to form three-dimensional images using Volocity4.4 (Improvision, PerkinElmer). Vessel formation was evaluated by counting the number of vessels that stained positive for fluorescein-conjugated ConA injected into the tail vein or VEGFR2 in five different areas (n 5 6), individual cell nuclei were identified by DAPI staining. Cell recovery solution (BD Biosciences) was used to collect cells from the recovered Matrigel plugs. In some studies, siRNA (7 mg) was mixed into the Matrigels and 10 mg of additional siRNA was injected into the implanted Matrigel after 3 days (n 5 6); the same amount of scrambled siRNA was used as a control. Gene knockdown was evaluated by counting the number of cells expressing each gene in the five different regions. In vivo analysis for retinal vessel formation. For gene knockdown in living retina, siRNA (0.5 mg) for each gene was injected intravitreally into one eye of a C57BL/6 mouse at P5 or P14, and the same amount of control siRNA was injected into the other eye. To overexpress genes, the complex of DNA (0.5 mg) for TFII-I and/or GATA2 and jetPEI transfection reagent (Polyplus transfection) was injected into the eye at P14. Vascular network formation in the retina was assessed 2 days after injection using flat-mounted, fluoresceinconjugated isolectin-staining and immunohistochemical analysis (n 5 7). Retinal RNA was purified and gene expression was quantified using qRT-PCR (n 5 7). Quantification of vessel density was performed with Adobe Photoshop.
